Our portfolio company and healthtech platform NeoDocs, which brings to you smartphone-based health-test kits, has raised $2 million in a seed funding round led by Omidyar Network India, along with participation from Titan Capital, Y Combinator, 9Unicorns and Gemba Capital.
Founded by IIT, Bombay alumni Nikunj Malpani, Anurag Meena and Pratik Lodha, Neodocs is developing an at-home testing platform that enables users to follow a couple of steps to apply a sample to a test card containing various chemicals. The card produces a visual output, such as a colour or intensity change, indicating biomarker levels. The Neodocs app on a smartphone then reads and interprets these results.
Neodocs has sold over 200,000 test cards till date and is being used by more than 4,000 doctors across India. The funds will be used to expand its footprint in international markets, including Europe, Australia, the Middle East, and the Americas and it will focus on its kidney care and urinary tract infections (UTI) kit. It also plans to enhance its self-diagnosis offerings by introducing a finger-prick blood test product that will provide results on a smartphone.
Speaking on the announcement, Nikunj Malpani, CEO and Co-founder, said, “India is often referred to as the chronic disease capital of the world, and this is largely due to lack of timely diagnosis. By enabling in-clinic testing Neodocs is empowering doctors to screen and diagnose patients instantly and start treatment immediately.”
Our portfolio company and healthtech platform NeoDocs, which brings to you smartphone-based health-test kits, has raised $2 million in a seed funding round led by Omidyar Network India, along with participation from Titan Capital, Y Combinator, 9Unicorns and Gemba Capital.
Founded by IIT, Bombay alumni Nikunj Malpani, Anurag Meena and Pratik Lodha, Neodocs is developing an at-home testing platform that enables users to follow a couple of steps to apply a sample to a test card containing various chemicals. The card produces a visual output, such as a colour or intensity change, indicating biomarker levels. The Neodocs app on a smartphone then reads and interprets these results.
Neodocs has sold over 200,000 test cards till date and is being used by more than 4,000 doctors across India. The funds will be used to expand its footprint in international markets, including Europe, Australia, the Middle East, and the Americas and it will focus on its kidney care and urinary tract infections (UTI) kit. It also plans to enhance its self-diagnosis offerings by introducing a finger-prick blood test product that will provide results on a smartphone.
Speaking on the announcement, Nikunj Malpani, CEO and Co-founder, said, “India is often referred to as the chronic disease capital of the world, and this is largely due to lack of timely diagnosis. By enabling in-clinic testing Neodocs is empowering doctors to screen and diagnose patients instantly and start treatment immediately.”